POS1166 GOUT AND SERIOUS KIDNEY DISEASE IN THE US: A NATIONAL PERSPECTIVE

Background There is a strong association between gout and kidney disease due to the kidney’s key role in uric acid excretion. 1-4 Several studies have also demonstrated that serum an independent risk factor for decline renal function 1,2 . are little national data available regarding clinical burden of patients US. Objectives To estimate percentage US hospitalizations with concomitant diagnosis either acute or chronic compared general population. Methods The Nationwide Inpatient Sample (NIS) stratified random sample all community hospitals. It only hospital database information on patients, regardless payer, including persons covered by Medicare, Medicaid, private insurance, uninsured. Detailed nonclinical elements each stay International Classification Diseases (ICD) 10 diagnosis, age, gender, length stay, charges, comorbidities etc. available. We examined failure (ICD10 codes N170-179), stages 3-5 N183-185), N19 (unspecified failure), end-stage code N186) (ICD M10.* M1A.*) these Results In 2019, there were 35.4 million all-cause Of these, 7.9 had serious (22.3%). 915,070 primary secondary (mean age 70.8 years, 68.4% men 31.6% women). 533,365 72.6 65.9% men) (58.3%, p<0.0001 population). Concomitant increased reaching 38.3% 65 years older population 62.5% (p<0.001). Table 1. Kidney disease-related hospitalization populations. GENERAL HOSPITALIZATIONS WITH COMORBID GOUT Patient Age Overall Hospitalizations N Serious Disease n (%) 18-44 8,356,284 622,170 (7.4%) 32,445 13,480 (41.5%) 45-64 8,440,831 2,160,220 (25.6%) 232,695 116,490 (50.1%) ≥65 13,421,154 5,257,220 (39.2%) 649,865 414,620 (83.8%) Total 2019 35,419,023 7,907,730 (22.3% ) (58.3% Note: numbers include 0-17 old. Conclusion Acute highly prevalent comorbid conditions overall hospitalizations. Among admitted gout, proportion dysfunction significantly higher affecting 58% high prevalence hospitalized may represent impactful component duration, complexity, costs care. References [1]Jung SW, et al. Am J Physiol Renal 2020;318:F1327-40. [2]Obermayr RP, Soc Nephrol 2008;19:2407-13. [3]Roughley MJ, Arthritis Res Ther 2015;17:90. [4]Juraschek SP, Semin Rheum 2013;42:551-61. Disclosure Interests Gurkirpal Singh Grant/research support from: Horizon Therapeutics (unrestricted research grant), Maanek Sehgal: None declared, Brad Marder Shareholder of: Therapeutics, Employee Brian LaMoreaux Alka Mithal: declared